Pharma Stocks
-
A Look At BridgeBio Pharma (BBIO) Valuation After New ATTR-CM, LGMD2I/R9 And TTR Antibody Updates
Why BridgeBio Pharma stock is back in focus BridgeBio Pharma (BBIO) has returned to the spotlight after management outlined fresh…
Read More » -
LIC raises stake in Sun Pharma to 5.04%. Details here
Life Insurance Corporation of India (LIC), insurance behemoth and India’s biggest institutional investor, raised its stake in the pharma company…
Read More » -
A Look At Ligand Pharmaceuticals (LGND) Valuation As Royalty Growth And Investment Plans Take Focus
Royalty growth outlook and capital deployment signal focus areas for investors Ligand Pharmaceuticals (LGND) recently highlighted an expected 40% royalty…
Read More » -
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13
NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of LGND dropped roughly 11% following the FDA’s decision…
Read More » -
Acadia sees $1.7B 2028 sales, pipeline updates
Key Terms phase 2 medical Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested…
Read More » -
Assessing UroGen Pharma (URGN) Valuation After ZUSDURI Secures Permanent J Code
UroGen Pharma (URGN) shares are in focus after the company reported that its bladder cancer therapy ZUSDURI now has a…
Read More » -
Insufficient Growth At NATCO Pharma Limited (NSE:NATCOPHARM) Hampers Share Price
When close to half the companies in India have price-to-earnings ratios (or “P/E’s”) above 25x, you may consider NATCO Pharma…
Read More » -
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 5.8% in the afternoon session after the company announced it had entered…
Read More » -
Is This Deep-Value Pharma Name Finally Near a Turning Poi
Bristol-Myers Squibb’s share price has been grinding lower, but fresh drug news, oncology milestones and a divided Wall Street are…
Read More » -
Tempus AI (TEM) Stock: Why Big Pharma Is Betting Big on This AI Platform
TLDR Tempus AI total contract value exceeded $1.1 billion, marking highest level in company history Company signed 70 data agreements…
Read More »